The Phase 3 HER2CLIMB-05 trial showed a 35.9% reduction in risk for patients treated with TUKYSA
HYMPAVZI’s safety profile was generally favorable
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
Comirnaty, Pfizer’s COVID-19 prevention vaccine, reported global sales of $1.15 billion
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents
Pfizer will participate in TrumpRx.gov, a direct-to-patient purchasing platform offering discount up to 85%
Under the partnership, the Pfizer INDovation program will empower DPIIT-recognized startups with grants of up to Rs. 60 lakhs each, along with a tailored 18-month incubation program delivered by Social Alpha
The ‘265 Patent is based on Enanta’s July 2020 patent application describing coronavirus protease inhibitors invented by Enanta scientists
Inclacumab was generally well tolerated in THRIVE-131
Subscribe To Our Newsletter & Stay Updated
